New Insights on Treating Neurodegeneretive Diseases Could Lead to New Classes of Clinical Trials for Alzheimer’s Disease

 

Scientists have been stumped for years on how to awaken stem cells to make new neurons in the human brain; a new study out of the journal Science Advances may have just unlocked critical insight into this neurogenerative puzzle through a roadmap of metabolic pathways. The study, which was conducted on adult and elderly mice, found that a unique gene in their genetically-mutated mice activated dormant neural stem cells, in effect generating new neurons in the brain. This discovery to awaken stem cells may lead to new clinical trials for treating people with neurodegenerative diseases, including an estimated 6.5 million Americans ages 65 and older who are living with Alzheimer’s in 2022.

With the increasing number of people developing these diseases, will there be many more discoveries down the road? Overall, clinical trials for Alzheimer’s disease medications are giving new options to patients.

“Alzheimer’s research is getting to a place where cancer research was maybe 30, 40 years ago,” says Anton Porsteinsson, MD, director of the Alzheimer’s Disease Care, Research and Education Program at the University of Rochester Medical Center in New York, as quoted in the Association of American Medical Colleges News. “I think we’re at a point where we’re going to see a logarithmic increase in discovery.”

Dr. Dung Trinh, MD, Chief Medical Officer of the Healthy Brain Clinic, which provides individualized plans for brain health with coaching and support including memory testing and brain health exams, gives his perspective on this new research and helps track the implications of this research for neurobiologists and for patients with neurodegenerative diseases.

Dung’s Thoughts

“Neural degeneration, otherwise known as the loss of brain cells, is a very common thread among pretty much all the neural degenerative diseases we have in the brain that includes Alzheimer’s disease and other dementias such as vascular dementia. It includes multiple sclerosis and Parkinson’s disease. The one underlying thread is the loss of brain cells, otherwise known as neurodegeneration.

So, this research actually is very exciting. We have not found a strategy to reproduce successfully more brain cells that have been less with these neurodegenerative diseases. And the best we’ve had so far is to hopefully try to slow down neurodegeneration, but the ability to create more brain cells, especially from stem cells that have been inactive in the brain, is a very exciting new revelation.

And this will lead to new classes of clinical trials and studies that will revolutionize this field. The field of neurodegeneration unfortunately have not caught up as far as finding new treatments and finding new medications due to the fact that we have not been able to successfully create or find a way to make new brain cells consistently. ”

Article written by Sonya Young.

Follow us on social media for the latest updates in B2B!

Image

Latest

courage
Creative Confidence and Moral Courage: The Leadership Traits Business Schools Should Be Betting On
May 25, 2026

What students need from higher education is becoming harder to pin down than it once was. As higher education faces mounting pressure—from student disengagement to the rapid rise of artificial intelligence—institutions are being forced to rethink not just what students learn, but who they become. New research and industry signals suggest that technical knowledge…

Read More
healthcare
From the C-Suite to the Classroom: A Healthcare Leader’s Bet on the Next Generation
May 25, 2026

Healthcare isn’t short on strategy right now—it’s short on people, access, and experienced leadership where it matters most. In Texas alone, more rural hospitals have closed than in any other state over the past decade, leaving entire communities with limited access to care. At the same time, many health systems are realizing they haven’t…

Read More
AI
The AI Health Score: Turning Hallucinations, Agents, and AI Risk Into Board-Ready Insight
May 24, 2026

As artificial intelligence moves deeper into enterprise operations, many organizations are discovering that the real challenge is not adoption, but control. Traditional software has always been predictable: the same input produces the same output, making it possible to audit systems at a fixed point in time. AI changes that equation. Jeff Carson, founder of…

Read More
TheAIAudit
Introducing TheAIAudit: A Platform Built to Measure, Monitor, and Govern Enterprise AI
May 22, 2026

Enterprise AI is advancing faster than most companies can govern it. Behind the scenes, AI systems are already influencing decisions tied to revenue, operations, compliance, customer outcomes, and risk — yet many organizations still lack a clear way to measure, explain, or oversee what those systems are doing. That is the gap TheAIAudit was…

Read More